Participated · Series A · May 2024

Latus Bio develops a gene therapy platform that pairs proprietary and engineered AAV capsids with clinically optimized routes of administration to enable efficient delivery at low doses. The company’s two lead programs are LTS-101 for CLN2 disease, which has IND clearance and multiple FDA designations, and LTS-201 for Huntington’s disease, which is being prepared for IND submission. Latus is advancing capsid variants for potential application beyond CNS disorders, including kidney, eye, heart, and muscle diseases. Management emphasizes scalability and lower-dose delivery to improve safety, manufacturability, and cost, targeting larger rare and broader CNS indications. The company raised $97 million in its Series A (including a $43 million extension) to fund operations through key clinical milestones for these programs.

Participated · Seed · Dec 2022

Zeraki builds mobile-first digital learning and school data analytics platforms to help schools manage student performance and administrative tasks. Its data analytics product lets teachers upload grades via mobile, generates performance breakdowns by student, subject or stream, integrates bulk messaging, and gives parents visibility into performance and fee payments. Zeraki also operates a digital learning platform with quizzes and performance tracking that gained traction during the COVID-19 pandemic. The company says more than 5,000 schools and roughly 2 million students use its data analytics platform, and its distribution covers almost half of Kenya’s high schools. Cofounded in 2014 by Isaac Nyangolo and Erick Oude, Zeraki plans to add administrative tools such as timetabling and payment products including fee loans. It currently operates in Kenya, Uganda and Guinea and aims to enter 10 new markets over the next three years. Zeraki raised external capital to grow its product catalog and support regional expansion.

Participated · Seed · Aug 2022

Intellischool, founded in 2018 by Dave Philp and Josh Turci, builds a SaaS data-analytics platform for the education sector that emphasizes automation, efficiency and meaningful data insights. The platform pulls data from multiple software sources to provide actionable insights to teachers, school administrators, students and parents intended to improve student performance and well-being. Intellischool leverages AI and cloud technologies, offering intuitive interfaces, configurable automation and advanced analytics to deliver timely, relevant data. The company is based in Melbourne, Australia and operates under Intellischool Holdings Pty Ltd. In August 2022 Intellischool raised A$3.3M in a seed round to support growth. The funds are earmarked to boost customer acquisition, enhance the product, and support expansion into primary and secondary schools in international markets.

Participated · Equity · Dec 2014

Abeona is developing CRISPR/Cas9‑based gene therapies, including programs targeting Fanconi anemia, Sanfilippo syndrome, and juvenile Batten disease. Its Fanconi anemia work is preclinical and focuses on delivering a correct copy of defective genes to restore DNA‑repair function. Researchers are engineering a protein–RNA complex using the Cas9 enzyme to recognize faulty DNA sequences and guide corrective genetic material. The company says its Sanfilippo program has involvement from patient advocacy groups. Abeona plans to begin clinical trials this year for at least one program. The company recently raised $8.5M to expand its gene‑therapy pipeline. Abeona Therapeutics is a Cleveland-based biotech developing gene therapy–based treatments for lysosomal storage diseases, with lead programs targeting MPS IIIA and IIIB. The company received Orphan Product Designations for MPS IIIA and IIIB in 2014. Abeona closed a $3.6M funding round to support its programs. The funds are intended to complete preclinical development of therapies for children with Sanfilippo syndrome (mucopolysaccharidosis type III), a rare terminal genetic disorder that typically causes death before the mid-teens. Clinical trials were anticipated to begin in early-to-mid 2015. The company is led by President/CEO Tim Miller, Ph.D.